Drugs / LY2880070
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02632448 | May 2016 → Apr 2025 | colon carcinoma, endometrial cancer, malignant pancreatic neoplasm, ovarian cancer +3 | Esperas Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05275426 | Mar 2022 → Aug 2025 | Ewing sarcoma, small cell sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2880070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275426 ↗ |
| Action | Inhibit | “the CHK1 inhibitor LY2880070” PMID 37819936 ↗ Dec 2023 |
| Modality | Small molecule | — CHEMBL5095250 ↗ |
| Route | Oral | “LY2880070 50 mg orally twice daily” PMID 37819936 ↗ Dec 2023 |
| Target | CHEK1 | “the CHK1 inhibitor LY2880070” PMID 37819936 ↗ Dec 2023 |